SNCA and Parkinson disease: Taking into consideration that α-synuclein immunohistochemistry is currently the gold standard in the neuropathological evaluation of PD (Stefanis, 2012), the development of personalized treatments to reduce the levels of both SNCA and α-synuclein is imperative and now achievable.